MedTrace Logo

Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)

NCT07227805 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2025-11-13

No results posted yet for this study

Summary

This study will demonstrate the safety and performance of the Novel Medtronic Experimental Automated Insulin Delivery system named MiniMed™ NMX8 system in people living with insulin-requiring diabetes in comparison with the MiniMed™ 780G system.

Conditions

  • Diabetes (Insulin-requiring, Type 1 or Type 2)

Interventions

DEVICE

780G

Subjects will continue to use the MiniMed™ 780G for 12 weeks

DEVICE

NMX8

Subjects will start using the MiniMed™ NMX8 system for 12 weeks

Sponsors & Collaborators

  • Medtronic Diabetes

    lead INDUSTRY

Principal Investigators

  • Pr. Ohad Cohen, MD · Medtronic Diabetes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2027-03-17
Completion
2027-03-17
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227805 on ClinicalTrials.gov